While settling in for a recent clinic appointment, a nurse reviewed my record and praised me for the breadth of my health history, noting how impressive I was for everything I had survived. This response isn’t uncommon when people learn that I had a heart and lung transplant. My nurse was…
A lack of the protein beta-arrestin 1 reduces the ability of pulmonary arteries to widen, leading to pulmonary hypertension (PH), according to a new study in mice. The study found that when beta-arrestin 1 is missing, the signaling pathway that drives the widening of pulmonary arteries, the blood vessels…
A clinical trial testing mosliciguat, an inhaled therapy for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), has wrapped up enrollment, and in less than one year since treating the first participant. That announcement was made by Pulmovant, the company developing the drug…
Cereno Scientific announced it will broaden development of its experimental treatment CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno had previously focused development of CS014 on idiopathic pulmonary fibrosis (IPF), a condition marked by progressive scarring (fibrosis) of the lungs with no known…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
